Abstract
Thyroid carcinoma is the most common endocrine malignancy; it is typified by a number of classical genomic insults, which tend to cluster with the discrete histologic subtypes. The most common of these is a mutation in B-RAF, which is present in approximately 44% (29% to 83%) of cases. In this review we have assessed the potential utility of a molecular test for somatically acquired mutations in B-RAF using thyroid malignancy as a model system according to 3 fundamental questions: would a test enhance our ability to distinguish benign from malignant, would a test unveil a risk factor not otherwise known, and would detecting a mutation enable a therapeutic option specific to those patients who carry the mutation?
Original language | English (US) |
---|---|
Pages (from-to) | 228-237 |
Number of pages | 10 |
Journal | Advances in anatomic pathology |
Volume | 13 |
Issue number | 5 |
DOIs | |
State | Published - Sep 2006 |
Keywords
- B-RAF
- Fine-needle aspiration
- Prognosis
- Thyroid carcinoma
ASJC Scopus subject areas
- Anatomy
- Pathology and Forensic Medicine